Frontiers in Pharmacology | Respiratory Pharmacology

Original Research

Published on 14 Mar 2024

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

in Respiratory Pharmacology

Cataldo Martucci
Andrew Dennis Allen
Nadia Moretto
Valentina Bagnacani
Alessandro Fioni
Riccardo Patacchini
Maurizio Civelli
Gino Villetti
Fabrizio Facchinetti

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1343941

3,467 views
3 citations

Original Research

Published on 13 Mar 2024

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats

in Respiratory Pharmacology

Nicole Reyne
Patricia Cmielewski
Alexandra McCarron
Ronan Smith
Elena Schneider-Futschik
Nina Eikelis
Piraveen Pirakalathanan
David Parsons
Martin Donnelley

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1362325

1,802 views
6 citations

Review

Published on 07 Mar 2024

The role of inflammation in silicosis

in Respiratory Pharmacology

Tong-Tong Liu
Hai-Fei Sun
Yan-Xing Han
Yun Zhan
Jian-Dong Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1362509

4,756 views
16 citations

Correction

Published on 07 Mar 2024

Corrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives

in Respiratory Pharmacology

Sicon Mitra
Uttpal Anand
Mimosa Ghorai
Balachandar Vellingiri
Niraj Kumar Jha
Tapan Behl
Manoj Kumar
Radha
Mahipal S. Shekhawat
Jarosław Proćków

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1365790

943 views

Original Research

Published on 23 Feb 2024

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

in Respiratory Pharmacology

Menglin He
Taoran Yang
Jian Zhou
Rurong Wang
Xuehan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1310286

4,230 views
5 citations

Original Research

Published on 21 Feb 2024

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

in Respiratory Pharmacology

Aleksandr S. Chernov
Maksim V. Rodionov
Vitaly A. Kazakov
Karina A. Ivanova
Fedor A. Meshcheryakov
Anna A. Kudriaeva
Alexander G. Gabibov
Georgii B. Telegin
Alexey A. Belogurov

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351655

2,701 views
4 citations

Original Research

Published on 13 Feb 2024

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

in Respiratory Pharmacology

Xuanyu Wu
Xiang Xiao
Hanyu Fang
Cuifang He
Hanyue Wang
Miao Wang
Peishu Lan
Fei Wang
Quanyu Du
Han Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1348708

4,475 views
1 citation

Original Research

Published on 07 Feb 2024

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

in Respiratory Pharmacology

Kuang-Ming Liao
Chung-Yu Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1309712

3,254 views
4 citations

Original Research

Published on 10 Jan 2024

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study

in Respiratory Pharmacology

Hélène Salvator
Elodie Lamy
Camille Roquencourt
Emmanuelle Bardin
Philippe Devillier
Stanislas Grassin-Delyle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1339835

1,319 views

Review

Published on 08 Jan 2024

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

in Respiratory Pharmacology

Diya Garg
Loretta G. Que
Jennifer L. Ingram

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1315540

3,843 views
8 citations

Case Report

Published on 08 Jan 2024

Case report: Fibrotic interstitial lung disease as the initial manifestation of hereditary pulmonary alveolar proteinosis caused by CSF2RB mutation

in Respiratory Pharmacology

Qiuhong Li
Huikang Xie
Manhui Li
Kebin Cheng

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252193

1,389 views

Original Research

Published on 12 Dec 2023

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis

in Respiratory Pharmacology

Jin-Young Huh
Jae Ha Lee
Jin Woo Song

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1301923

4,891 views
8 citations

Review

Published on 11 Dec 2023

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis

in Respiratory Pharmacology

Liangtao Wen
Lixiang Xie
Fengying Gong
Shunan Zhang
Tieju Xi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1277284

2,814 views
3 citations

Editorial

Published on 06 Dec 2023

Editorial: Novel therapeutic strategies for the treatment of respiratory diseases

in Respiratory Pharmacology

Serena Di Vincenzo
Maria Ferraro
Maria Letizia Manca
Josè Esteban Peris
Elisabetta Pace

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1340116

1,134 views

Original Research

Published on 06 Dec 2023

Vitamin E stabilizes iron and mitochondrial metabolism in pulmonary fibrosis

in Respiratory Pharmacology

Jing Chang
Jiahui Wang
Beibei Luo
Weihao Li
Ziyue Xiong
Chaoqi Du
Xue Wang
Yuejiao Wang
Jingya Tian
Shuxin Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1240829

3,233 views
4 citations

Review

Published on 06 Dec 2023

Potential role of irisin in lung diseases and advances in research

in Respiratory Pharmacology

Hongna Dong
Xuejiao Lv
Peng Gao
Yuqiu Hao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1307651

4,033 views
5 citations